文献速递支持与姑息治疗头颈与中枢神经肿瘤

alisertib联合白蛋白紫杉醇治疗晚期实体瘤的I期研究

Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies.
PubMed 文献 · Eur J Cancer · 2021-07-10

这是一项两部分I期研究,A部分采用标准3+3设计确定alisertib联合白蛋白紫杉醇的最大耐受剂量,B部分在难治性高级别神经内分泌肿瘤等患者中扩展。共31例患者接受治疗,最大耐受剂量为alisertib 40 mg每日两次每周第1-3天联合白蛋白紫杉醇100mg/m2每周给药(3周用药1周休息),剂量限制性毒性为中性粒细胞减少。联合方案副作用可控,在高级别神经内分泌肿瘤中显示初步疗效。

要点

  • alisertib联合白蛋白紫杉醇的最大耐受剂量为alisertib 40 mg每日两次每周第1-3天联合白蛋白紫杉醇100mg/m2每周给药(3周用药1周休息)。
  • 剂量限制性毒性为中性粒细胞减少,其他常见副作用包括疲劳、黏膜炎和腹泻。
  • 在高级别神经内分泌肿瘤中观察到初步疗效,支持进一步研究。

核心结论

  • alisertib联合白蛋白紫杉醇副作用可控,在高级别神经内分泌肿瘤中显示初步疗效,值得进一步测试。

研究设计与样本

  • 两部分I期研究,A部分采用标准3+3设计进行剂量递增确定最大耐受剂量,B部分为剂量扩展。
  • 共31例患者入组接受治疗,A部分16例,B部分15例。
  • B部分主要入组难治性高级别神经内分泌肿瘤患者,15例中13例为高级别神经内分泌肿瘤。

主要发现

  • A部分中一例小细胞肺癌患者获得部分缓解并治疗超过2年。
  • A部分另有4例患者获得疾病稳定,分别为胰腺导管腺癌1例、小细胞肺癌2例、高级别神经内分泌肿瘤1例。
  • B部分13例高级别神经内分泌肿瘤患者中,1例获得部分缓解,4例疾病稳定超过10个月。

关键数值与推荐

  • 最大耐受剂量为alisertib 40 mg每日两次每周第1-3天联合白蛋白紫杉醇100mg/m2每周给药,3周用药1周休息。
  • 剂量限制性毒性为中性粒细胞减少。
  • 其他常见副作用包括疲劳、黏膜炎和腹泻。

临床怎么用

  • 该联合方案的最大耐受剂量和毒性谱可为后续研究设计提供参考。
  • 在难治性高级别神经内分泌肿瘤中观察到部分缓解和持续疾病稳定,提示该联合方案值得在此类患者中进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Aurora kinase A (AURKA) is a pleiotropic serine/threonine kinase that orchestrates mitotic progression. Paclitaxel stabilises microtubules and disrupts mitotic spindle assembly. The combination of AURKA inhibitor (alisertib) plus paclitaxel may be synergistic in rapidly proliferative cancers. We evaluated the safety and maximum tolerated dose (MTD) of alisertib in combination with nab-paclitaxel and its preliminary efficacy in patients with refractory high-grade neuroendocrine tumours (NETs). METHOD: This is a two-part, Phase 1 study. In Part A (dose escalation), a standard 3 + 3 design was used to determine MTD. In Part B (dose expansion), patients with predominantly refractory high-grade NETs were enrolled. RESULTS: In total, 31 patients were enrolled and treated (16 in Part A and 15 in Part B). The MTD of alisertib was 40 mg BID on D1-3 per week and nab-paclitaxel 100mg/m2 weekly: 3 weeks, 1 week off. Dose-limiting toxicity was neutropenia, and other common side-effects included fatigue, mucositis, and diarrhoea. In Part A, a patient with small-cell lung cancer with partial response (PR) was treated for more than 2 years, whereas four other patients with pancreatic ductal adenocarcinoma (one patient), small cell lung cancer (SCLC) (two patients), or high-grade NET (one patient) achieved stable disease (SD). In Part B, 13 of 15 enrolled patients had high-grade NETs. Of these, one had PR, and four had SD for more than 10 months. CONCLUSIONS: The combination of alisertib and nab-paclitaxel has manageable side-effect profile and showed promising preliminary efficacy in high-grade NETs, warranting further testing. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01677559.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lim KH, Opyrchal M, Acharya A, et al. Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies. Eur J Cancer. 2021. PMID: 34256279. doi:10.1016/j.ejca.2021.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。